Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 7Phase 1/2 4Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Skin Neoplasms 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Melanoma 1Leukemia, Myeloid, Acute 1Leukemia 1Depression 1

Interventions

Dexamethasone 8Oxycodone 6Epoetin Alfa 5Propofol 4Palonosetron 4Meropenem 4Zoledronic Acid 3Vancomycin 3Sevoflurane 3Ondansetron 3Naloxone 3Everolimus 3Ciprofloxacin 3Cholecalciferol 3Ceftazidime 3Cefepime 3Calcium Dobesilate 3Bevacizumab 3Aspirin 3Aprepitant 3peginterferon alfa-2a 2edoxaban 2apixaban 2apatinib 2Vitamin B 12 2Vincristine 2Tobacco Use Cessation Devices 2Teicoplanin 2Tablets 2Surgical Procedures, Operative 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Neoplasms × Interleukin-2 × Clear all
NCT00352885 2018-09-14

Effectiveness of Escitalopram in Preventing or Reducing Depressive Symptoms in People Receiving Interleukin-2 Treatment

Emory University

Phase 4 Completed
20 enrolled 11 charts

Depression, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡